| scholarly article | Q13442814 |
| P2093 | author name string | D Klinzmann | |
| J D Medh | |||
| J T Stapleton | |||
| S Wünschmann | |||
| W N Schmidt | |||
| P2860 | cites work | Binding of hepatitis C virus to CD81 | Q22004178 |
| Structure-function analysis of hepatitis C virus envelope-CD81 binding | Q24525189 | ||
| Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans | Q24673759 | ||
| Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
| Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells | Q27469312 | ||
| Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein | Q27469553 | ||
| Cell fusion activity of hepatitis C virus envelope proteins | Q27469594 | ||
| Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection | Q27469669 | ||
| Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein | Q27469721 | ||
| Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets | Q27469739 | ||
| Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR | Q27480320 | ||
| Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor | Q27485871 | ||
| Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes | Q27486195 | ||
| CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system | Q28271422 | ||
| Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate | Q29618060 | ||
| Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA. | Q33959072 | ||
| Fluorescence-based quantitative methods for detecting human immunodeficiency virus type 1-induced syncytia. | Q33968924 | ||
| A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate | Q34070135 | ||
| Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C | Q34200730 | ||
| Microbial adherence to and invasion through proteoglycans | Q35533138 | ||
| CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses | Q35921103 | ||
| Normal lymphocyte development but delayed humoral immune response in CD81-null mice | Q36377129 | ||
| Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro | Q36390620 | ||
| Rotaviruses induce an early membrane permeabilization of MA104 cells and do not require a low intracellular Ca2+ concentration to initiate their replication cycle. | Q36548599 | ||
| Hepatitis C: progress and problems | Q36642065 | ||
| Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line | Q37061606 | ||
| Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. | Q39875541 | ||
| Suramin blocks hepatitis C binding to human hepatoma cells in vitro | Q40972540 | ||
| Low density lipoprotein receptor as a candidate receptor for hepatitis C virus | Q40972546 | ||
| Hepatitis C virus: detection of intracellular virus particles by electron microscopy | Q41235560 | ||
| Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines | Q41577111 | ||
| Hepatitis C: the clinical spectrum of disease | Q41598735 | ||
| Proteins are cointernalized with virion particles during early infection | Q41913367 | ||
| Modification of membrane permeability during Semliki Forest virus infection | Q41916567 | ||
| Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins | Q42978052 | ||
| Direct detection of hepatitis C virus (HCV) RNA from whole blood, and comparison with HCV RNA in plasma and peripheral blood mononuclear cells. | Q42978951 | ||
| Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells. | Q42981975 | ||
| Association of hepatitis C virus in human sera with beta-lipoprotein | Q42982426 | ||
| A role for hepatitis C virus infection in type II cryoglobulinemia | Q42983385 | ||
| Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients | Q42983474 | ||
| Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: plasma HCV RNA analysis underestimates circulating virus load | Q42983600 | ||
| Hepatitis C virus: buoyant density of the factor VIII-derived isolate in sucrose | Q42984652 | ||
| Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. | Q42985058 | ||
| Establishment of persistent hepatitis C virus infection and replication in vitro. | Q42985215 | ||
| Antibodies against hepatitis C virus in mixed cryoglobulinemia patients | Q42986062 | ||
| Hepatitis C virus (HCV) infection and cryoglobulinemia: analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology | Q42997613 | ||
| In vitro infection of peripheral blood mononuclear cells by hepatitis C virus | Q43037693 | ||
| Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication | Q43048290 | ||
| Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins | Q43049359 | ||
| Clinical outcomes after transfusion-associated hepatitis C. | Q44746801 | ||
| Posttransfusion non-A, non-B hepatitis in chimpanzees. Physicochemical evidence that the tubule-forming agent is a small, enveloped virus | Q45839124 | ||
| First cysteine-rich repeat in ligand-binding domain of low density lipoprotein receptor binds Ca2+ and monoclonal antibodies, but not lipoproteins. | Q52831885 | ||
| Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia | Q69238529 | ||
| Characterization of monoclonal antibodies against human low density lipoprotein | Q72688759 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virology | Q7215 |
| lipoprotein | Q28350 | ||
| hepatitis C | Q154869 | ||
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 10055-62 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor | |
| P478 | volume | 74 |
| Q33648339 | A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81. |
| Q43042430 | A study of susceptibility of primary human Kupffer cells to hepatitis C virus |
| Q37805839 | Adaptive Immunity to the Hepatitis C Virus |
| Q44490223 | Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction |
| Q27477568 | An 85-aa segment of the GB virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T cells |
| Q38825949 | An insight into the molecular characteristics of hepatitis C virus for clinicians |
| Q27472891 | Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles |
| Q39912694 | Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo |
| Q27478309 | Apolipoprotein 3 allele is associated with persistent hepatitis C virus infection |
| Q27486923 | Apolipoprotein C1 Association with Hepatitis C Virus |
| Q27490234 | Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor |
| Q27473044 | Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density Gradients |
| Q44893793 | Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. |
| Q27472837 | Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines |
| Q27486525 | Binding of liver derived, low density hepatitis C virus to human hepatoma cells |
| Q35546564 | Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents |
| Q40653700 | CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo |
| Q29619745 | CD81 is required for hepatitis C virus glycoprotein-mediated viral infection |
| Q27485659 | CD81-Dependent Binding of Hepatitis C Virus E1E2 Heterodimers |
| Q36385222 | Cell entry of hepatitis C virus |
| Q43037514 | Cell surface expression of LDL receptor in chronic hepatitis C: correlation with viral load |
| Q37514366 | Cellular and molecular biology of HCV infection and hepatitis |
| Q38352468 | Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate |
| Q40706735 | Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption |
| Q27472884 | Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles |
| Q27486387 | Characterization of a Peptide Domain within the GB Virus C NS5A Phosphoprotein that Inhibits HIV Replication |
| Q36598453 | Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication |
| Q27477720 | Characterization of an Immunodominant Antigenic Site on GB Virus C Glycoprotein E2 That Is Involved in Cell Binding |
| Q40539381 | Characterization of functional hepatitis C virus envelope glycoproteins. |
| Q27473226 | Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses |
| Q26784234 | Chronic hepatitis C virus infection and lipoprotein metabolism |
| Q27473461 | Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein |
| Q36548487 | Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment |
| Q40530808 | Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner |
| Q27481043 | Do high lipids help clearance of hepatitis C? |
| Q36927297 | ERK signaling is triggered by hepatitis C virus E2 protein through DC-SIGN |
| Q46879484 | Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy |
| Q24674235 | Entry of feline calicivirus is dependent on clathrin-mediated endocytosis and acidification in endosomes |
| Q34004118 | Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions |
| Q35621603 | Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation |
| Q45729692 | Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection |
| Q35059730 | Flow cytometric detection of hepatitis C virus antigens in infected peripheral blood leukocytes: binding and entry. |
| Q27469312 | Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells |
| Q33579851 | Functional selection of hepatitis C virus envelope E2-binding Peptide ligands by using ribosome display |
| Q36530370 | GB Virus Type C Envelope Protein E2 Elicits Antibodies That React with a Cellular Antigen on HIV-1 Particles and Neutralize Diverse HIV-1 Isolates |
| Q40589291 | HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing |
| Q30438047 | HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation |
| Q37829769 | HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia |
| Q90523108 | Hepatitis C Virus Entry: An Intriguingly Complex and Highly Regulated Process |
| Q36712605 | Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men |
| Q39755223 | Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions |
| Q38337047 | Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses |
| Q43047968 | Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes |
| Q36946317 | Hepatitis C virus entry |
| Q34016463 | Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy |
| Q34235286 | Hepatitis C virus experimental model systems and antiviral drug research |
| Q24551041 | Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR |
| Q27477687 | Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles |
| Q36244165 | Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2. |
| Q38003914 | Hepatitis C virus: a new class of virus associated with particles derived from very low-density lipoproteins |
| Q34970582 | Hepatitis C: molecular virology and antiviral targets |
| Q26779128 | Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection |
| Q34197528 | Human liver transplantation as a model to study hepatitis C virus pathogenesis |
| Q27477468 | Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding |
| Q27487399 | Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies |
| Q24291799 | Identification of a hepatic factor capable of supporting hepatitis C virus replication in a nonpermissive cell line |
| Q34403294 | Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assay |
| Q43039598 | Identification of human hepatocyte protein(s), which binds specifically to the recombinant envelope-2/non-structural-1 protein of hepatitis C virus |
| Q27472909 | Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81 |
| Q50934385 | Immunopathogenesis of Hepatitis C Virus Infection. |
| Q59200582 | Immunopathogenesis of hepatitis C virus infection |
| Q40211269 | Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. |
| Q26864485 | Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization |
| Q34422731 | In search of hepatitis C virus receptor(s). |
| Q35716330 | Infection of Human Liver Myofibroblasts by Hepatitis C Virus: A Direct Mechanism of Liver Fibrosis in Hepatitis C |
| Q34295937 | Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. |
| Q30767073 | Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. |
| Q34772253 | Interaction between hepatitis C virus proteins and host cell factors |
| Q42827093 | Interaction of L-SIGN with hepatitis C virus envelope protein E2 up-regulates Raf-MEK-ERK pathway |
| Q27472900 | Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry |
| Q35195465 | Lipid Profiles and Hepatitis C Viral Markers in HCV-Infected Thalassemic Patients |
| Q36010861 | Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus |
| Q38166372 | Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection |
| Q42997915 | Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. |
| Q35669529 | Mechanisms of hepatitis C virus infection |
| Q39692571 | Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis C virus glycoproteins |
| Q38109628 | New insights in recurrent HCV infection after liver transplantation |
| Q29620681 | Novel insights into hepatitis C virus replication and persistence |
| Q24795289 | Potential cellular receptors involved in hepatitis C virus entry into cells |
| Q34576190 | Potential treatment options and future research to increase hepatitis C virus treatment response rate |
| Q37352203 | Primary hepatocytes as targets for hepatitis C virus replication |
| Q27473382 | Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection |
| Q57568884 | Rationale and Design of LAPLACE-2: A Phase 3, Randomized, Double-Blind, Placebo- and Ezetimibe-Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy |
| Q36956517 | Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents |
| Q27473084 | Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. |
| Q30375044 | Recombinant hepatitis C virus-envelope protein 2 interactions with low-density lipoprotein/CD81 receptors. |
| Q40573089 | Recombinant hepatitis C virus-like particles expressed by baculovirus: utility in cell-binding and antibody detection assays. |
| Q40585135 | Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment |
| Q21090530 | Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus |
| Q27485298 | Serum-Derived Hepatitis C Virus Infection of Primary Human Hepatocytes Is Tetraspanin CD81 Dependent |
| Q30756955 | Structural characterization of peptide fragments from hCD81-LEL. |
| Q27481034 | Studying Hepatitis C Virus: Making the Best of a Bad Virus |
| Q27478383 | Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells |
| Q27470936 | Tetraspanins in viral infections: a fundamental role in viral biology? |
| Q24609524 | The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae |
| Q34158687 | The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. |
| Q44054976 | Translated Alu sequence determines nuclear localization of a novel catalytic subunit of casein kinase 2. |
| Q38350416 | Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection. |
| Q41926409 | Yellow fever virus, but not Zika or Dengue virus inhibits T cell receptor-mediated T cell function by an RNA-based mechanism |
| Q78318877 | [Interaction of the hepatitis C virus with the cellular membrane] |
Search more.